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MicroRNA-340 Inhibits Esophageal Cancer

Introduction
Esophageal cancer, which includes esophageal squamous cell carcinoma (ESCC) and adenocarcinoma of the esophagus, is the eighth most common cancer worldwide and the sixth most common cause of cancer-related death [1, 2] . ESCC accounts for 60-70% of all cases of esophageal cancer in the world and it is more common in the developing world, occurring at a rate 20 to 30 times higher in China than in the United States [3, 4] . ESCC arises from the epithelial cells lining the esophagus and its incidence is associated with tobacco smoking, alcohol consumption, hot drinks and a poor diet [1] . ESCC is an aggressive cancer that is often diagnosed at later stages of the disease, which may explain the high mortality associated with this malignancy.
MicroRNAs (miRNAs) are small (18-25 nucleotides) noncoding RNAs that negatively regulate gene expression via base pairing to complementary sequences in the 3′ untranslated region (3′-UTR) of target mRNAs [5] . Approximately 1000 miRNAs have been identified in the human genome, and up to 30% of genes are thought to be regulated by miRNAs [6] . Aberrant expression of miRNAs is associated with several diseases including cancer, and tumor-associated miRNAs can function as tumor suppressors or oncogenes depending on their target mRNAs [7] [8] [9] [10] [11] . MiR-340 is an extensively studied miRNA that plays a tumor suppressor role in several cancers including breast, colorectal and gastric cancers [12] [13] [14] . MiR-340 was shown to suppress tumor growth in osteosarcoma via targeting the rho-associated protein kinase 1 (ROCK1, a serine/threonine protein kinase involved in the regulation of the actin cytoskeleton [15] . In ESCC, several aberrantly expressed miRNAs have been identified in microarray or qRT-PCR analyses, including miR-340 [16, 17] ; however, the role of miR-340 in ESCC has not been investigated to date.
Cancer cells need to alter metabolic pathways to support rapid cell growth and proliferation, and metabolic processes involving the synthesis of serine and glycine are essential to meet these requirements [18] . Several enzymes involved in one-carbon metabolism, which is a system of biological reactions that facilitates the cycling of onecarbon units for the biosynthesis of cellular components and the maintenance of redox status, are associated with tumorigenesis [19, 20] . Among these enzymes, phosphoglycerate dehydrogenase (PHGDH), and phosphoserine aminotransferase 1 (PSAT1), which catalyze the biosynthesis of serine, are upregulated in several cancers and are suggested to contribute to the pathogenesis of human cancer by diverting the glucose flux towards serine metabolism [20] . However, the mechanisms regulating the expression of these enzymes and the contribution of alterations in metabolic pathways to tumor cell proliferation and growth are not entirely clear.
In the present study, we explored the expression and function of miR-340 in vitro and in vivo and examined the mechanisms underlying its activity. We showed that miR-340 is downregulated in ESCC tumor tissues and cell lines and identified PSAT1 as its direct target. Our results suggest that miR-340 acts as a tumor suppressor in ESCC, and its effects on the progression and invasiveness of ESCC are mediated by the downregulation of PSAT1, suggesting potential novel biomarkers and therapeutic targets for the treatment of ESCC.
Materials and Methods
Patients and Tissue Specimens
A total of 64 patients diagnosed with ESCC between 2004 and 2007 at the Tongren Hospital, who underwent esophageal cancer resection prior to the administration of chemotherapy were included in the study. ESCC and carcinoma-adjacent tissues were collected immediately after surgical resection, and confirmed by experienced pathologists. Tissues were dissected manually to remove connective tissue and stored in liquid nitrogen immediately until use. All samples were obtained from the Tissue Bank of Tongren Hospital and coded anonymously in accordance with local ethical guidelines (as stipulated by the Declaration of Helsinki). Written informed consent was obtained from all patients, and the protocol was 
Cell Lines and Culture Conditions
The immortalized human esophageal endothelial cell line HEEC was purchased from Sciencell Research Laboratories (Sciencell, Carlsbad, CA, USA) and grown in Epithelial Cell Medium-2 (Sciencell) supplemented with epithelial cell growth supplement-2 (ScienCell). Human embryonic kidney HEK293T cells and three ESCC cell lines (EC1, EC109, and EC9706) were purchased from the Chinese Academy of Medical Science (Shanghai, China) and are routinely maintained in our lab in DMEM or RPMI 1640 medium (GIBCO, Carlsbad, CA) supplemented with 10% fetal bovine serum, 100 units/ml penicillin G, and 100 µg/ ml streptomycin at 37°C in humidified air containing 5% CO 2 .
Quantitative Real-Time PCR Total cellular RNA was isolated from cells using Trizol (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. RNA was eluted with RNase-free water, quantified by measuring absorbance at 260/280 nm, and used for reverse transcription reactions.
The expression of miR-340 was measured by TaqMan assay (Applied Biosystems, Foster City, CA). MiRNA and gene expression were normalized using endogenous U6.
For PSAT1, cDNA was synthesized by oligo(dT) priming using the RevertAid TM First Strand cDNA Synthesis Kit (Fermentas, Canada) according to the manufacturer's instructions. Real-time quantitative PCR was performed with a commercial SYBR-Green master mix kit (Takara) using an Applied Biosystems Prism 7900 Sequence Detection System. GAPDH was used as an internal control. Each sample was measured in triplicate. The primer sequences are shown in Table 1 .
Plasmid constructs and lentiviral transduction
To generate the miR-340 overexpressing lentiviral vector pCDH-miR-340, a fragment encoding the pre-miR-340 sequence was amplified by PCR from human genomic DNA and then cloned into the BamHI/ EcoRI sites of the pCDH-CMV-EF1-copGFP vector (SBI, Mountain View, CA, USA) with the following primers: forward, 5′-AAA GAA TTC ATC AAG ATC ACG TTT AAT ATG TGC-3′; reverse, 5′-AAA GGA TCC GGT TCA CTC TTC TTC CAC ACGTA-3′. Constructs and insertions were confirmed by DNA sequencing.
The pcDNA3 vector was used to generate a PSAT1 overexpression plasmid. The full-length human PSAT1 cDNA sequence was amplified by PCR using cDNA isolated from HL60 cells in which PSAT1 expression is rich as the template, and the primers used were as follows: forward, 5′-AAA GAA TTC ATG GAC GCC CCC AGG CAG-3′; reverse, 5′-AAA GGA TCC TCA TAG CTG ATG CAT CTC CAA AAAT-3′. Then the PSAT1 cDNA gene was cloned into the BamHI/EcoRI restriction sites.
The 3′-UTR of PSAT1 containing an intact miR-340 recognition sequence was amplified by PCR from genomic DNA using the primers 5′-CCC CCT CGA GAC ACA TCC TAA CCA GGA TAT ACTCT-3′ and 5′-AAA AGC GGC CGC GGG GAA AGA CTT TTC AGC AAAG-3′. Then the PCR products were subcloned into a psiCHECK-2 TM Vector (Promega, Madison, WI). A psiCHECK-2 TM construct containing the PSAT1 3′-UTR with mutations in the seed sequence was synthesized with a QuikChange Site-Directed Mutagenesis Kit (Stratagene; Agilent Technologies, Palo Alto, CA).
For production of viral particles, the lentivirus-mediated PSAT1 packaging system containing pCDH-CMV-EF1-copGFP or pCDH-miR-340, Rec, TAT, Gag, and Vsvg was transfected into HEK293T cells using Lipofectamine™ 2000 (Invitrogen) according to the manufacturer's instructions. The supernatant containing the virus source was collected 60 h post-transfection and filtered through a 0.45-μm pore membrane (Millipore). Cells were grown to log phase and then transfected with either pCDH-CMV-EF1-copGFP (vector) or pCDH-miR-340 for 24 h. Stable cell lines were screened by mass sorting on a FACSAria flow cytometer (BD Biosciences, Mountain View, CA, USA) based on the expression of GFP carried by the lentiviral vector 72 h after transfection.
Gene transfection ESCC cells (5 × 10 6 ) in 2 ml of culture medium were transfected with 100 pmol of control vector or PSAT1 cDNA mixed with Lipofectamine 2000 reagent in serum reduced medium according to the manufacturer's instructions. The medium was changed to complete culture medium after 6 h, and the cells were incubated at 37°C in a CO 2 incubator for an additional 48 h before harvest.
Luciferase reporter assays HEK-293T cells were cotransfected with 50 nM of either miR-340 mimic or the negative control and 500 ng of psiCHECK2-PSAT1-3′-UTR-wt or psiCHECK-2-PSAT1-3′-UTR-mut. Cells were collected 48 h after transfection and analyzed using the Dual-Luciferase Reporter Assay System (Promega, San Luis Obispo, CA). Luciferase activity was detected using a GloMax fluorescence reader (Promega, San Luis Obispo, CA). A psiCHECK-2 vector that provides constitutive expression of Renilla luciferase was cotransfected as an internal control.
Invasion assays
For cell invasion assays, an 8 µm pore filter membrane (Corning, Acton, MA) was coated with Matrigel (diluted at 1:5) (BD Biosciences) in serum-free RPMI 1640. After air-drying and sterilization, 29 µl of the plain medium with serum was added to the lower chamber of the Costar Transwell (Corning). Cells transfected as indicated were trypsinized, resuspended in serum-free RPMI 1640 at a density of 1.2×10 6 cells/ml, seeded in 50 µl in the upper chamber, and incubated at 37°C for 20 h. Non-invading cells remaining on the upper surface of the filter were removed with a cotton swab and rinsed with PBS several times; cells that appeared on the lower surface of the filter were fixed with methanol for more than 15 min at -20°C and then washed in PBS, stained with crystal violet and counted under a microscope.
Proliferation assay
To measure cell viability, cells treated as indicated were seeded into 96-well plates at a density of 4×10 3 cells/well/200 µL in maintenance medium. Viable cells were quantified at 24, 48, 72 and 96 h after the seeding by the chromogenic 3-[4, 5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium-bromide (MTT) assay according to the manufacturer's instructions (Sigma, St. Louis, US). Each assay was performed in triplicate and repeated three times.
Colony formation assay
Colony formation assays were performed using a previously described method [13] . Briefly, cells were digested with trypsin and suspended into a single cell status. Approximately 6000 cells from each group were cultured in a 60 mm diameter culture dish with 10% FBS for 14 days. The colonies were fixed and stained with 0.5% crystal violet for 15 min, and then washed three times. Colonies consisting of more than 50 cells were defined as one colony. The number of colonies in 10 random view fields was counted under a microscope and the average representing the 95% confidence region was achieved. The experiment was performed three independent times. 
Tumorigenicity in BALB/c Scid Mice
Results
MiR-340 is downregulated in ESCC cell lines and tissues
Carcinoma and adjacent non-tumor tissues from 64 ESCC patients were analyzed by qRT-PCR to compare the levels of miR-340 expression. The results showed that miR-340 expression was significantly lower in tumor tissues than in adjacent non-tumor tissues (p < 0.01) (Fig. 1A) . MiR-340 was significantly downregulated in the ESCC cell lines EC1, EC109, and EC9706 compared to the human esophageal endothelial cell line HEEC, with the lowest levels of miR-340 expression observed in EC9706 cells followed by EC109 cells (Fig. 1B) . Therefore, these two cell lines were used for subsequent experiments.
MiR-340 suppresses ESCC cell growth in vitro and in vivo
To investigate the role of miR-340 in ESCC, cells were transfected with a miR-340 overexpression vector and cell viability and tumor growth were measured. Overexpression of miR-340 in the EC109 and EC9706 cell lines was confirmed by qRT-PCR ( Fig. 2A) . MiR-340 overexpression significantly inhibited cell viability and colony formation in EC109 and EC9706 cells as determined by the MTT and colony forming assays ( Fig. 2B and C) . Assessment of tumor growth in a mouse xenograft model showed that tumor weight was significantly lower in mice injected with miR-340 overexpressing EC9706 cells than in those injected with vector control cells (p < 0.021) (Fig. 2D) . 
MiR-340 suppresses invasion in ESCC cell lines
To further explore the effect of miR-340 on ESCC, cells transfected with or without a miR-340 overexpressing vector were analyzed by Matrigel invasion assays. The results showed that miR-340 overexpression significantly inhibited the invasion of EC109 and EC9706 cells by approximately 60% of the control (p <0.01) (Fig. 3A and B) .
PSAT1 is a direct target gene of miR-340
To further explore the regulating mechanisms of miR-340, we examined its potential targets using prediction tools. A conserved domain within the 3′-UTR of PSAT1 with two potential miR-340 binding sites was identified using the prediction algorithm of Targetscan (Fig. 4A) . To confirm this prediction, luciferase assay was performed to validate PSAT1 as a target of miR-340. HEK293 cells were co-transfected with luciferase reporter constructs generated by cloning the wild-type or mutant 3′-UTR of PSAT1 carrying mutations in the miR-340 seed region and the miR-340 overexpressing vector or control vector. Assessment of binding sites mutations of PSAT 3′-UTR (Fig. 4B) . Ectopic expression of miR-340 significantly downregulated the mRNA expression of PSAT1 relative to that of the GAPDH control in both EC109 and EC9706 cells (Fig. 4C) , further confirming that PSAT1 is a target of miR-340. The effect of miR-340 on tumor invasiveness was further examined by western blot analysis of the expression of the epithelial marker E-cadherin, the epithelial-mesenchymal transition (EMT) markers Snail and Vimentin, and the Ser/Thr kinase GSK-3β. The transcription factor Snail regulates the expression of E-cadherin, and downregulation of E-cadherin induces EMT [21] . GSK-3β is a Ser/Thr kinase that is inactivated by phosphorylation at Ser9; it phosphorylates and regulates Snail activity, and it maintains the epithelial phenotype by inhibiting Snail, and inactivation of GSK-3β promotes EMT. As shown in Fig. 4D , overexpression of miR-340 upregulated E-cadherin, downregulated Snail and Vimentin, and reduced the levels of phosphorylated and total GSK-3β concomitant with the downregulation of PSAT1, indicating that miR-340 might suppresse EMT in correlation with the downregulation of its target PSAT1 in ESCC cells.
PSAT1 is involved in miR-340-induced suppression of ESCC cell proliferation and invasion
To confirm the relationship between the miR-340/PSAT1 axis and the regulation of ESCC cell proliferation and invasion, PSAT1 was ectopically expressed in ESCC cells and cell viability and invasiveness were assessed. The results showed that ectopic expression of PSAT1 partially rescued the inhibition of cell proliferation and invasion induced by miR-340 overexpression in both EC109 and EC9706 cells (Fig. 5A and B) . Consistently, ectopic expression of PSAT1 partially restored the levels of E-cadherin and Snail/Vimentin down- regulated by miR-340, respectively, suggesting that PSAT1 reverses the effect of miR-340 on suppressing EMT in ESCC cells (Fig. 5C) . qRT-PCR analysis of miR-340 and PSAT1 expression in samples from patients with ESCC showed a negative correlation between the mRNA levels of PSAT1 and the expression of miR-340 (r 2 = 0.3073, p < 0.01), further confirming that miR-340 regulates the expression of PSAT1 in ESCC (Fig. 6) .
Discussion
In the present study, we explored the expression and role of miR-340 in ESCC and the mechanisms underlying its activity. We show that miR-340 is downregulated in ESCC cell lines and tissues and its overexpression inhibits cell viability, colony formation, and invasion in vitro and tumor growth in a mouse xenograft model in vivo. We identified PSAT1 as a direct target of miR-340 and showed that its expression is negatively correlated with that of miR-340 in ESCC tumor samples. Our results suggest that miR-340 acts as a tumor suppressor by modulating the expression of PSAT1, and its downregulation may contribute to the progression and invasiveness of ESCC.
Esophageal cancer is an aggressive malignancy associated with a poor prognosis, and the 5-year survival rate of ESCC patients is approximately 19% [22, 23] . The high mortality rate of ESCC can be partly attributed to the fact that it is typically diagnosed at an advanced stage, underscoring the need to identify biomarkers for the early detection of this disease. Several studies have focused on identifying miRNAs associated with esophageal cancer using microarray or expression analyses. Guo et al. reported the results of a miRNA array containing 509 miRNA sequences in which miRNA expression in 31 matched ESCC and normal tissues was compared [24] . This study identified 7 miRNAs capable of distinguishing ESCC from normal tissues, among which three (miR-25, miR-424, and miR-151) were upregulated and four (miR-100, miR-99a, miR-29c and miR-140) were downregulated in ESCC. In a microarray analysis of 210 human miRNAs, four miRNAs, let-7d, miR-330, miR-340, and miR-373, were upregulated in ESCC tumors [16] . Ogawa et al. analyzed 73 miRNAs by qRT-PCR and identified six upregulated miRNAs and four downregulated miRNAs in ESCC tissues compared to paired normal tissues, whereas Kano et al. used Taqman human miRNA array to examine 365 human miRNAs and found 15 downregulated miRNAs in ESCC tissues [25, 26] . Only a few miRNAs overlap among these studies, indicating that the involvement of miRNAs in ESCC is complex and requires further investigation. Among the miRNAs consistently shown to act as tumor suppressors in ESCC, miR-203, miR-205, miR-10a, and miR375 have been shown to be downregulated in ESCC compared to non-tumor tissues [16, 27] . We showed that miR-340 is downregulated in tumor tissues compared to adjacent nontumor tissues and in ESCC cell lines, and its expression is associated with the viability, colony formation ability and invasiveness of ESCC cell lines and tumor growth in a mouse model.
Although several studies have examined the role of miRNAs in esophageal cancer, few potential targets have been identified. Three miRNAs (miR-145, miR-133a, and miR-133b) [26] . miR-133a was shown to act as a tumor suppressor in ESCC by targeting CD47 [28] , and miR-25 was shown to interact with and inhibit the activity of CDH1, a known tumor suppressor that encodes E-cadherin, suggesting that miR-25 promotes ESCC cell migration and invasion by downregulating CDH1 [29] . Other miRNAs and their targets involved in ESCC include miR-518b and Rap1b, miR-196a and Rap1a, miR-223 and FBXW7, miR-150 and ZEB1, and miR-143 and ERK5 [30] . Here, we showed that miR-340 acts as a tumor suppressor in ESCC by targeting PSAT1. Overexpression of miR-340 downregulated PSAT1, and ectopic expression of PSAT1 reversed the miR-340 induced inhibition of cell proliferation, invasion and EMT. Alterations in the expression of enzymes of the serine biosynthesis pathway, including PHGDH and PSAT1, have been associated with several cancers.
In breast cancer, an RNAi based loss of function screening revealed that overexpression of enzymes involved in the serine biosynthesis pathway is required for in vivo tumorigenesis [31] . PHGDH was shown to be upregulated in certain breast cancers, and suppression of PSAT1 inhibited the proliferation of PHGDH overexpressing breast cancer cell lines [32, 33] . PSAT1 is overexpressed in colorectal cancer and is associated with chemoresistance, and increased levels of PSAT1 mRNA have been detected in colon adenocarcinoma, and correlated with tumor stage in colon cancer [31] . In breast cancer, PSAT1 is associated with poor responses to endocrine therapy [33] . These studies demonstrate the involvement of PSAT1 in tumorigenesis and support our present results suggesting that the downregulation of miR-340 may contribute to tumorigenesis in ESCC via the upregulation of PSAT1. Further studies focusing on the relation between miR-340 and PSAT1 may clarify their roles in ESCC development and progression.
Conclusions
The results of the present study indicate that miR-340 acts as a tumor suppressor in ESCC via the modulation of the expression of its target PSAT1, a serine biosynthesis pathway enzyme associated with tumorigenesis in several cancers. Our results showing that the effects of miR-340 on cell proliferation and invasion are reversed by the ectopic expression of PSAT1 and that the expression of these proteins is negatively correlated in ESCC samples confirm that miR-340 exerts its effects through PSAT1 and suggest potential novel biomarkers in ESCC.
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